GAITHERSBURG, Md., Oct. 22, 2025 /PRNewswire/ -- Novavax, Inc. today announced that it has further executed against its planned transformation into a lean, agile operating model by signing definitive ...
Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed ...
Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsLuis Sanay - Vice President of Investor RelationsJohn Jacobs ...
Adjusted Total Revenue is a non-GAAP financial measure. Adjusted Total Revenue is total revenue excluding Sanofi Supply Sales, Sanofi Royalties and Sanofi Influenza-COVID-19 Combination and Matrix-M ...
Vaccine biotechnology company Novavax (NASDAQ:NVAX) in Q3 CY2025, but sales fell by 16.6% year on year to $70.45 million. The company expects the full year’s revenue to be around $1.05 billion, close ...
Novavax, Inc. (Nasdaq: NVAX), today announced that it will participate in the following upcoming investor conferences: ...
Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look that exciting either. Novavax (NASDAQ: NVAX) was once a leading contender to ...
A webcast of the fireside chat will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcast will be available for 30 days. SOURCE Novavax, ...
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-reports-second-quarter-2025-financial-results-and-operational-highlights ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results